Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is emerging as a promising biomarker for immunotherapy response in cancer patients. TMB can be quantitated by a number of NGS-based sequencing technologies. Whole Exome Sequencing (WES) allows comprehensive measu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fancello, Laura, Gandini, Sara, Pelicci, Pier Giuseppe, Mazzarella, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631597/
https://www.ncbi.nlm.nih.gov/pubmed/31307554
http://dx.doi.org/10.1186/s40425-019-0647-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631597/
https://www.ncbi.nlm.nih.gov/pubmed/31307554
http://dx.doi.org/10.1186/s40425-019-0647-4

Ejemplares similares